FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912943831> ?p ?o ?g. }

• W2912943831 endingPage "3296" @default.
• W2912943831 startingPage "3296" @default.
• W2912943831 abstract "Abstract Background: The ubiquitin-proteasome system (UPS) has been validated as a target in multiple myeloma (MM) through the success of proteasome inhibitors such as bortezomib, but drug resistance is an emerging challenge. Targeting some of the upstream components of the UPS, such as the E1 ubiquitin activating enzyme (UAE), could therefore be a promising alternative. TAK-243 (MLN7243) specifically blocks the ubiquitin conjugation cascade through the formation of a TAK-243-ubiquitin adduct, thereby inhibiting the UAE. Our aim was to explore the effectiveness of TAK-243 against pre-clinical myeloma models, and to understand some its mechanisms of action. Methods: We performed pre-clinical studies in myeloma cell lines and mouse models using TAK-243. Downstream effects were evaluated using viability, apoptosis assays, western blotting, gene expression profiling (GEP), and Reverse Phase Protein Array (RPPA) techniques. Results: MM1.S and MOLP-8 TP53 wild-type cell lines were sensitive to TAK-243, with median inhibitory concentrations (IC50) of 25 nM at 24 hours based on viability assays. In otherwise isogenic cell lines in which TP53 was suppressed using genome editing techniques, the IC50 was ~40 nM, but higher TAK-243 concentrations of 100 nM overcame resistance due to TP53 inactivation. Similarly, TAK-243 was able to overcome resistance to both conventional (dexamethasone) and novel (bortezomib, lenalidomide) drugs in paired sensitive and resistant cell line models. After treatment with TAK-243, Annexin V and TO-PRO3 staining determined that viable MM1.S cells were induced into early or late apoptosis. This was accompanied by a significant increase in cleaved caspase-3, -8, and -9 as detected by flow cytometry, and in cleaved caspase-7 detected by RPPA and western blot. Exposure to TAK-243 reduced the cellular content of ubiquitin-protein conjugates, and did not enhance expression levels of a fusion protein degraded by the proteasome in a ubiquitin-independent manner, indicating the lack of direct proteasome inhibition. GEP analysis and RPPA detected enhanced expression of p53-pathway related proteins, including MDM2, TP53, and p21 in TAK-243 treated MM1.S cells. Several mRNAs and proteins in the ER stress pathway, including ATF6, ATF4, IRE1a and XBP1 were also elevated, as were many non-coding RNAs and DNA-damage related genes. Combination experiments in MM cell lines demonstrated synergy between TAK-243 and lenalidomide, pomalidomide, panobinostat, melphalan and doxorubicin. Finally, TAK-243 demonstrated in vivo antitumor activity against MM1.S and MOLP-8 xenograft models when dosed at 12.5 mg/kg IV twice-weekly for 2 weeks (tumor growth inhibition of 60% and 73%, respectively). Elevation of BiP, ATF4, XBP1s and cleaved-caspase 3 was detected within the first 24 hrs after dosing in the sensitive MM1.S xenografts. In contrast, RPMI 8226 cells, which showed a 2000 nM IC50 in cell culture, were also resistant to TAK-243 in vivo, with no tumor growth inhibition detected. Conclusions: TAK-243 is a UAE inhibitor that is active against myeloma cells in vitro and in xenograft models in vivo, overcomes conventional and novel drug resistance, and its action is associated with stimulation of the TP53 and ER stress pathways. Thus, it may deserve further evaluation as an anti-myeloma agent. Disclosures Berger: Takeda Pharmaceuticals: Employment. Hyer:Takeda Pharmaceuticals: Employment. Chattopadhyay:Takeda Pharmaceuticals: Employment. Syed:Takeda Pharmaceuticals: Employment. Shi:Takeda Pharmaceuticals: Employment. Yu:Takeda Pharmaceuticals International Co, Cambridge, MA: Employment. Shinde:Takeda Pharmaceuticals: Employment. Kreshock:Takeda Pharmaceuticals: Employment. Tirrell:Takeda Pharmaceuticals: Employment. Menon:Takeda Pharmaceuticals: Employment. Orlowski:Takeda Pharmaceuticals: Research Funding." @default.
• W2912943831 created "2019-02-21" @default.
• W2912943831 creator A5010026747 @default.
• W2912943831 creator A5021818898 @default.
• W2912943831 creator A5022210435 @default.
• W2912943831 creator A5027048541 @default.
• W2912943831 creator A5027266596 @default.
• W2912943831 creator A5027501007 @default.
• W2912943831 creator A5030715835 @default.
• W2912943831 creator A5035815873 @default.
• W2912943831 creator A5038235561 @default.
• W2912943831 creator A5043711943 @default.
• W2912943831 creator A5048362577 @default.
• W2912943831 creator A5053725057 @default.
• W2912943831 creator A5053916580 @default.
• W2912943831 creator A5062871565 @default.
• W2912943831 creator A5081592114 @default.
• W2912943831 creator A5081840794 @default.
• W2912943831 creator A5083819346 @default.
• W2912943831 date "2016-12-02" @default.
• W2912943831 modified "2023-10-17" @default.
• W2912943831 title "The Anti-Tumor Effect of the Ubiquitin-Activating Enzyme (UAE) Inhibitor TAK-243 on Pre-Clinical Models of Multiple Myeloma" @default.
• W2912943831 doi "https://doi.org/10.1182/blood.v128.22.3296.3296" @default.
• W2912943831 hasPublicationYear "2016" @default.
• W2912943831 type Work @default.
• W2912943831 sameAs 2912943831 @default.
• W2912943831 citedByCount "5" @default.
• W2912943831 countsByYear W29129438312017 @default.
• W2912943831 countsByYear W29129438312018 @default.
• W2912943831 countsByYear W29129438312019 @default.
• W2912943831 countsByYear W29129438312021 @default.
• W2912943831 crossrefType "journal-article" @default.
• W2912943831 hasAuthorship W2912943831A5010026747 @default.
• W2912943831 hasAuthorship W2912943831A5021818898 @default.
• W2912943831 hasAuthorship W2912943831A5022210435 @default.
• W2912943831 hasAuthorship W2912943831A5027048541 @default.
• W2912943831 hasAuthorship W2912943831A5027266596 @default.
• W2912943831 hasAuthorship W2912943831A5027501007 @default.
• W2912943831 hasAuthorship W2912943831A5030715835 @default.
• W2912943831 hasAuthorship W2912943831A5035815873 @default.
• W2912943831 hasAuthorship W2912943831A5038235561 @default.
• W2912943831 hasAuthorship W2912943831A5043711943 @default.
• W2912943831 hasAuthorship W2912943831A5048362577 @default.
• W2912943831 hasAuthorship W2912943831A5053725057 @default.
• W2912943831 hasAuthorship W2912943831A5053916580 @default.
• W2912943831 hasAuthorship W2912943831A5062871565 @default.
• W2912943831 hasAuthorship W2912943831A5081592114 @default.
• W2912943831 hasAuthorship W2912943831A5081840794 @default.
• W2912943831 hasAuthorship W2912943831A5083819346 @default.
• W2912943831 hasConcept C104317684 @default.
• W2912943831 hasConcept C153911025 @default.
• W2912943831 hasConcept C185592680 @default.
• W2912943831 hasConcept C190283241 @default.
• W2912943831 hasConcept C203014093 @default.
• W2912943831 hasConcept C25602115 @default.
• W2912943831 hasConcept C27740335 @default.
• W2912943831 hasConcept C2776063141 @default.
• W2912943831 hasConcept C2776192174 @default.
• W2912943831 hasConcept C2776364478 @default.
• W2912943831 hasConcept C2777478702 @default.
• W2912943831 hasConcept C2778305200 @default.
• W2912943831 hasConcept C2778367456 @default.
• W2912943831 hasConcept C2780225316 @default.
• W2912943831 hasConcept C502942594 @default.
• W2912943831 hasConcept C53227056 @default.
• W2912943831 hasConcept C54355233 @default.
• W2912943831 hasConcept C55493867 @default.
• W2912943831 hasConcept C64927066 @default.
• W2912943831 hasConcept C81885089 @default.
• W2912943831 hasConcept C86803240 @default.
• W2912943831 hasConcept C88634738 @default.
• W2912943831 hasConceptScore W2912943831C104317684 @default.
• W2912943831 hasConceptScore W2912943831C153911025 @default.
• W2912943831 hasConceptScore W2912943831C185592680 @default.
• W2912943831 hasConceptScore W2912943831C190283241 @default.
• W2912943831 hasConceptScore W2912943831C203014093 @default.
• W2912943831 hasConceptScore W2912943831C25602115 @default.
• W2912943831 hasConceptScore W2912943831C27740335 @default.
• W2912943831 hasConceptScore W2912943831C2776063141 @default.
• W2912943831 hasConceptScore W2912943831C2776192174 @default.
• W2912943831 hasConceptScore W2912943831C2776364478 @default.
• W2912943831 hasConceptScore W2912943831C2777478702 @default.
• W2912943831 hasConceptScore W2912943831C2778305200 @default.
• W2912943831 hasConceptScore W2912943831C2778367456 @default.
• W2912943831 hasConceptScore W2912943831C2780225316 @default.
• W2912943831 hasConceptScore W2912943831C502942594 @default.
• W2912943831 hasConceptScore W2912943831C53227056 @default.
• W2912943831 hasConceptScore W2912943831C54355233 @default.
• W2912943831 hasConceptScore W2912943831C55493867 @default.
• W2912943831 hasConceptScore W2912943831C64927066 @default.
• W2912943831 hasConceptScore W2912943831C81885089 @default.
• W2912943831 hasConceptScore W2912943831C86803240 @default.
• W2912943831 hasConceptScore W2912943831C88634738 @default.
• W2912943831 hasIssue "22" @default.
• W2912943831 hasLocation W29129438311 @default.
• W2912943831 hasOpenAccess W2912943831 @default.
• W2912943831 hasPrimaryLocation W29129438311 @default.
• W2912943831 hasRelatedWork W2149340130 @default.

• next